Mild Cognitive Impairment or Mild Neurocognitive Disorder: Implications for Clinical Practice. Hypothesized Key Players in the Pathogenesis of AD
|
|
- Vernon Martin
- 6 years ago
- Views:
Transcription
1 AD is a Neurodegenerative Disease as Seen in the PET Scan and is Characterized by Amyloid Plaques and Neurofibrillary Tangles Mild Cognitive Impairment or Mild Neurocognitive Disorder: Implications for Clinical Practice George T. Grossberg, MD Samuel W. Fordyce Professor Director, Geriatric Psychiatry Program Department of Psychiatry St. Louis University School of Medicine St. Louis, Missouri Neuritic Plaques Neurofibrillary Tangles PET scans from UCLA Center on Aging. AD = Alzheimer s disease; PET = positron emission tomography. Accessed July 1, Nelson PT, et al. J Neuropathol Exp Neurol. 2009;68(1):1-14. Hypothesized Key Players in the Pathogenesis of AD Aβ = amyloid beta; ApoE4 = apolipoprotein E-ε4. Mucke L. Nature. 2009;461(7266): Established Risk Factors Older age Family history of AD APOE-ε4 gene (especially amnestic subtype) CV disease and associated CV risk factors (eg, smoking, diabetes, hyperlipidemia, hypertension, obesity) Less education Traumatic brain injury Elevated plasma homocysteine levels Risk Factors Emerging Risk Factors Inflammation Chronic kidney disease Thyroid dysfunction Dietary factors and activity level Social isolation Depression CV = cardiovascular; = mild cognitive impairment. Alzheimer s Association Alzheimer s Disease Facts and Figures. Accessed July 1, de Bruijn RF, et al. BMC Med. 2014;12:130. Subjective Cognitive Impairment Diagnosis of Mild Cognitive Impairment and Alzheimer s Disease SCI, also referred to as Senior Moments, is not in the SCI may represent a prodrome to Mild Neurocognitive Disorder (formerly called ) SCI = subjective cognitive impairment.
2 Terminology: An Update Delirium Delirium Mild Neurocognitive Disorder Major Neurocognitive Disorder Replaces DSM-IV Delirium, Mild Cognitive Impairment, and Dementia Preclinical AD due to AD All-cause dementia AD dementia Probable AD dementia Possible AD dementia Dementia unlikely to be due to AD Disturbance in attention and awareness Develops over short period of time, and tends to fluctuate in severity during the day An additional cognitive domain disturbance Physiologic consequence of a medical condition, substance intoxication or withdrawal, toxin exposure, or multiple etiologies The Confusion Assessment Method (CAM) is considered the best screening tool for delirium AA = Alzheimer s Association; NIA = National Institute on Aging. Edition. Arlington, VA: American Psychiatric Association; Sperling RA, et al. Alzheimers Dement. 2011;7(3): Albert MS, et al. Alzheimers Dement. 2011;7(3): McKhann GM, et al. Alzheimers Dement. 2011;7(3): Edition. Arlington, VA: American Psychiatric Association; Inouye SK, et al. Ann Intern Med. 1990;113(12): The Continuum of AD Defining a Preclinical Stage of AD () Cognitive Function Preclinical Aging Stage 1 Asymptomatic amyloidosis High PET amyloid tracer retention Low CSF A 1-42 Stage 2 Amyloidosis + Neurodegeneration Neuronal dysfunction on FDG-PET/fMRI High CSF tau/p-tau Cortical thinning/hippocampal atrophy on smri Biomarker evidence of AD without clinical symptoms of cognitive decline Years Dementia Stage 3 Amyloidosis + Neurodegeneration + Subtle Cognitive Decline Evidence of subtle change from baseline level of cognition Poor performance on more challenging cognitive tests Does not yet meet criteria for AD Dementia Sperling RA, et al. Alzheimers Dement. 2011;7(3): CSF = cerebrospinal fluid; FDG = fluorodeoxyglucose; fmri = functional magnetic resonance imaging; smri = structural MRI. Sperling RA, et al. Alzheimers Dement. 2011;7(3): Cognitive and Behavioral Domains That May Be Affected in or Dementia Attention * Sustained and divided attention, processing speed Executive function/ability * Planning/decision making/judgment Reasoning and handling of complex tasks Learning and memory * Immediate and recent recall, free recall, cued recall and recognition Ability to acquire and remember new information Language * Expressive and receptive Speaking, reading, writing Visuoconstructionalperceptual activity/visuospatial abilities * Social cognition Emotions and behavioral regulation Changes in personality, behavior, or comportment *;. Edition. Arlington, VA: American Psychiatric Association; Albert MS, et al. Alzheimers Dement. 2011;7(3): McKhann GM, et al. Alzheimers Dement. 2011;7(3): Mild Neurocognitive Disorder/ Cognitive deficits do not occur exclusively in context of delirium Self- or informantreported cognitive complaint Objective cognitive impairment Preserved functioning No dementia due to AD Exclusion of vascular, traumatic, medical causes of cognitive decline (when possible) Evidence of longitudinal decline in cognition (when feasible) History consistent with AD genetic factors (when relevant) Edition. Arlington, VA: American Psychiatric Association; Albert MS, et al. Alzheimers Dement. 2011;7(3):
3 Major Neurocognitive Disorder (A Syndrome) / Dementia (Major Neurocognitive Disorder) Evidence of significant cognitive decline in 1 cognitive domains Significant cognitive decline noted by patient, informant, or clinician Objective evidence of substantial impaired cognition, preferably by standard neuropsychological testing Symptoms interfere with ability to function at work or at everyday activities Not explained by delirium or () major psychiatric disorder (Dementia) Evidence of cognitive or behavioral impairment involving 2 domains Noted in history-taking from patient and knowledgeable informant Objective cognitive assessment ( bedside mental status examination or neuropsychological testing) Represent a decline from previous levels of functioning and performing Edition. Arlington, VA: American Psychiatric Association; McKhannGM, et al. Alzheimers Dement. 2011;7(3): Major Neurocognitive Disorder Due to AD / Probable AD Dementia Criteria met for probable AD Either: Evidence of a causative AD genetic mutation (< 1% of all AD) OR All 3 of the following Decline in memory and learning plus at least 1 other cognitive domain Steady, gradual decline without extended plateaus No evidence of mixed etiology Not better explained by CV disease, another neurodegenerative disorder, or another mental, neurologic, or systemic disorder Initial/most prominent cognitive deficits evident on history and examination in 1 of the following Amnestic presentation* Nonamnestic presentations Criteria met for major Diagnosis should not be applied neurocognitive disorder/dementia Insidious onset and gradual progression when there is evidence of Substantial concomitant cerebrovascular disease A specified neurodegenerative disorder OR Another concurrent, active neurological disease, or a non-neurological medical comorbidity or use of medication that could substantially affect cognition *Deficits include impairment in learning and recall of recently learned information as well as evidence of cognitive dysfunction in at least 1 other cognitive domain; Most prominent deficits in word-finding (language presentation), spatial cognition (visuospatial presentation), and impaired reasoning, judgment, and problem solving (executive dysfunction); Core features of Dementia with Lewy bodies other than dementia itself, prominent features of behavioral variant fronterotemporal dementia, or prominent features of semantic variant primary progressive aphasia. Edition. Arlington, VA: American Psychiatric Association; McKhann GM, et al. Alzheimers Dement. 2011;7(3): The Office-Based Assessment of Neurocognitive Disorder A careful history from a family member/reliable informant Quantify cognitive function, eg, Mini Mental State Exam (MMSE), Montreal Cognitive Assessment (MOCA), St. Louis University Mental Status Evaluation (SLUMS) ADL screening (Barthel Inventory or Katz Index of ADL) Screening neurological exam Laboratory: CMP, CBC, TSH, B12/folate; UA; RPR, HIV testing, if indicated; some also recommend: Vitamin D level; CRP; homocysteine level MRI or CT (old stroke, tumor, NPH, frontotemporal atrophy) Complete neuropsychological testing (if available) Repeat cognitive assessment in 6 to 12 months to confirm/clarify diagnosis, measure disease trajectory Importance of early recognition Benefits of Early Diagnosis in AD Allows patient and family to learn about AD Allows time for future planning while patient still capable, eg, update will; health care proxy; POA Allows clinician to begin AD medications early and to educate patient and family about lifestyle interventions, which may slow disease progression or delay onset in family members Allows participation in clinical trials ADL = activities of daily living; CBC = complete blood count; CMP = complete metabolic profile; CRP = C- reactive protein; NPH = normal pressure hydrocephalus; RPR = rapid plasma reagin; TSH = thyroid stimulating hormone; UA = urinalysis. Weiner MF, et al (Eds). Clinical Manual of Alzheimer Disease and Other Dementias. Arlington, VA: American Psychiatric Publishing; POA = power of attorney. Natural History: Symptom Progression in and AD Amyloid and Tau Biomarkers in SCI MMSE Score 30 Mild, Mild AD 25 subjective Forgetfulness Objective Short-term Moderate AD Memory loss memory loss 20 Progression of cognitive Normal ADL Repetitive deficits function questions Aphasia 15 Hobbies, Severe AD Dysexecutive syndrome interest loss Agitation Impaired basic ADLs Impaired 10 Altered sleep instrumental Transitions in care patterns functions Total 5 Anomia dependence: dressing, feeding, bathing Years Amyloid and Tau biomarker profiles become increasingly abnormal from SCI to to AD Amyloid and Tau biomarkers are unable to differentiate between SCI and healthy controls but may be able to differentiate between SCI patients who cognitively decline over time vs those who do not Estimates of duration of survival following diagnosis of AD range from 3 to 12 years. Feldman H, et al. Accessed July 5, Feldman HH, et al. Neurology. 2005;65(6 Suppl 3):S10-S17. Kua EH, et al. Psychogeriatrics. 2014;14(3): Colijn MA, et al. J Alzheimers Dis. 2015;47(1):1-8.
4 FDG-PET and Neuropsychological Testing in SCI 24 women with SCI followed for 24 months Changes in cognitive domain scores and regional cerebral metabolic rate of glucose measured Significant reduction in executive functions found without changes in other cognitive domains Declines in regional glucose metabolism found Change in executive function was positively correlated with decreased glucose metabolism in the right posterior cingulate gyrus Risk Factors for SCI APOE-ε4 genotype Especially in those 70 years of age Positive amyloid PET and/or Tau PET findings Presence of anxiety or depression (may mimic SCI vs risk factor) Jeong HS, et al. Acta Neurol Scand. 2016;[Epub ahead of print]. Krell-Roesch J, et al. J Neuropsychiatry Clin Neurosci. 2015;27(4): Colijn MA, et al. J Alzheimers Dis. 2015;47(1):1-8. Yates JA, et al. Aging Ment Health. 2015;[Epub ahead of print]. Predictors of Clinical Progression from SCI to CREDOS study from South Korea enrolled 129 participants with SCI Follow-up duration of 0.5 to 4.7 years Median time to event was 3.64 years Predictors of conversion from SCI to Older age Lower MMSE score APOE-ε4 carrier Lower verbal delayed recall score Predictors of Clinical Progression from SCI to (continued) Presence of white matter hyperintensities Worried complainers Low general life satisfaction CREDOS = Clinical Research Centers for Dementia of South Korea. Hong YJ, et al. Dement Geriatr Cogn Disord. 2015;40(3): Benedictus MR, et al. Stroke. 2015;46(9): Mendonca MD, et al. Am J Alzheimers Dis Other Demen. 2015;31(2): Peitsch L, et al. Int Psychogeriatr. 2016;28(7): Conversion from to AD Not all patients convert to AD Usually 50% of patients convert to AD over 5 years Stress reduction (meditation, yoga), spiritual fitness, dietary modification, physical exercise, mental stimulation, and socialization may delay progression from to AD The 12 Years Preceding Due to AD: The Temporal Emergence of Cognitive Decline Investigated the prodromal phase of over a 12-year period in 27 initially healthy participants with subsequent preceding AD (NC-) vs 60 matched healthy individuals (NC-NC) Sequence of cognitive decline Began with verbal memory and savings: 8 years preceding Verbal episodic learning, visual memory, semantic memory (animal fluency): 4 years preceding Executive functioning, psychomotor speed, and informant-based reports: 2 years preceding Khalsa DS. J Alzheimers Dis. 2015;48(1):1-12. Mistridis P, et al. J Alzheimers Dis. 2015;48(4):
5 Treatment of SCI/ Conclusion No FDA approved therapies exist Recent SCI study using fish oil (EPA+DHA: 2.4 g/dl, n = 11) vs placebo (corn oil, n = 10) for 24 weeks Results: Increased RBC Omega-3 content Improved working memory Improved cortical blood oxygen level-dependent (BOLD) activity during working memory challenge SCI is a prodrome to, which is a prodrome to AD SCI is not listed in the ; however, a variety of biomarkers, as well as clinical features enable us to diagnose SCI There is growing evidence that anxiety and depression may mimic SCI There is growing evidence that lifestyle modification may slow progression from SCI to to AD EPA = eicosapentaenoicacid; DHA = docosahexaenoic acid. Boespflug EL, et al. J Nutr Health Aging. 2016;20(2): Practical Take-Aways There is growing evidence that Mild Neurocognitive Disorder (), especially of the amnestic type, is a risk factor/prodrome to AD Clinicians need to advise their at-risk patients to: 1) Control any and all cardiovascular risk factors including hypertension, hyperlipidemia, diabetes, obesity, smoking, lack of exercise 2) Keep mentally, physically, socially and spiritually active 3) Treat/avoid stress/anxiety/depression, eg, mindfulness/relaxation therapy 4) Avoid head trauma (protect the brain) 5) Adopt a Mediterranean Diet By following these guidelines, patients have a better chance of delaying/decreasing their risk of AD
DISCLOSURES. Objectives. THE EPIDEMIC of 21 st Century. Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia NONE TO REPORT
Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia DISCLOSURES NONE TO REPORT Freddi Segal Gidan, PA, PhD USC Keck School of Medicine Rancho/USC California Alzheimers Disease
More informationMild Cognitive Impairment (MCI)
October 19, 2018 Mild Cognitive Impairment (MCI) Yonas E. Geda, MD, MSc Professor of Neurology and Psychiatry Consultant, Departments of Psychiatry & Psychology, and Neurology Mayo Clinic College of Medicine
More informationComments to this discussion are invited on the Alzforum Webinar page. Who Should Use the New Diagnostic Guidelines? The Debate Continues
Comments to this discussion are invited on the Alzforum Webinar page. Who Should Use the New Diagnostic s? The Debate Continues Ever since new criteria came out for a research diagnosis of prodromal/preclinical
More informationMild Cognitive Impairment
Mild Cognitive Impairment Victor W. Henderson, MD, MS Departments of Health Research & Policy (Epidemiology) and of Neurology & Neurological Sciences Stanford University Director, Stanford Alzheimer s
More informationDEMENTIA? 45 Million. What is. WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: 70% Dementia is not a disease
What is PRESENTS DEMENTIA? WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: Memory Reasoning Planning Learning Attention Language Perception Behavior AS OF 2013 There
More informationForm D1: Clinician Diagnosis
Initial Visit Packet Form D: Clinician Diagnosis NACC Uniform Data Set (UDS) ADC name: Subject ID: Form date: / / Visit #: Examiner s initials: INSTRUCTIONS: This form is to be completed by the clinician.
More informationDiagnosis and Treatment of Alzhiemer s Disease
Diagnosis and Treatment of Alzhiemer s Disease Roy Yaari, MD, MAS Director, Memory Disorders Clinic, Banner Alzheimer s Institute 602-839-6900 Outline Introduction Alzheimer s disease (AD)Guidelines -revised
More informationDementia. Assessing Brain Damage. Mental Status Examination
Dementia Assessing Brain Damage Mental status examination Information about current behavior and thought including orientation to reality, memory, and ability to follow instructions Neuropsychological
More informationNew diagnostic criteria for Alzheimer s disease and mild cognitive impairment for the practical neurologist
New diagnostic criteria for Alzheimer s disease and mild cognitive impairment for the practical neurologist Andrew E Budson, 1,2 Paul R Solomon 2,3 1 Center for Translational Cognitive Neuroscience, VA
More informationDementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada
Dementia Update October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada Outline New concepts in Alzheimer disease Biomarkers and in vivo diagnosis Future trends
More informationWHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient
DEMENTIA WHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient Progressive and disabling Not an inherent aspect of
More informationHOW TO PREVENT COGNITIVE DECLINE.AT MCI STAGE?
EAMA CORE CURRICULUM HOW TO PREVENT COGNITIVE DECLINE.AT MCI STAGE? Sofia Duque Orthogeriatric Unit São Francisco Xavier Hospital Occidental Lisbon Hospital Center University Geriatric Unit, Faculty of
More informationImaging of Alzheimer s Disease: State of the Art
July 2015 Imaging of Alzheimer s Disease: State of the Art Neir Eshel, Harvard Medical School Year IV Outline Our patient Definition of dementia Alzheimer s disease Epidemiology Diagnosis Stages of progression
More informationAlzheimer s disease dementia: a neuropsychological approach
Alzheimer s disease dementia: a neuropsychological approach Dr. Roberta Biundo, PhD Neuropsychology Coordinator at Parkinson s disease and movement disorders unit of San Camillo rehabilitation hospital
More informationRegulatory Challenges across Dementia Subtypes European View
Regulatory Challenges across Dementia Subtypes European View Population definition including Early disease at risk Endpoints in POC studies Endpoints in pivotal trials 1 Disclaimer No CoI The opinions
More informationOverview. Case #1 4/20/2012. Neuropsychological assessment of older adults: what, when and why?
Neuropsychological assessment of older adults: what, when and why? Benjamin Mast, Ph.D. Associate Professor & Vice Chair, Psychological & Brain Sciences Associate Clinical Professor, Family & Geriatric
More informationNeuropsychological Evaluation of
Neuropsychological Evaluation of Alzheimer s Disease Joanne M. Hamilton, Ph.D. Shiley-Marcos Alzheimer s Disease Research Center Department of Neurosciences University of California, San Diego Establish
More informationALZHEIMER S DISEASE OVERVIEW. Jeffrey Cummings, MD, ScD Cleveland Clinic Lou Ruvo Center for Brain Health
ALZHEIMER S DISEASE OVERVIEW Jeffrey Cummings, MD, ScD Cleveland Clinic Lou Ruvo Center for Brain Health Prevalence AD: DEMOGRAPHY AND CLINICAL FEATURES Risk and protective factors Clinical features and
More informationErin Cullnan Research Assistant, University of Illinois at Chicago
Dr. Moises Gaviria Distinguished Professor of Psychiatry, University of Illinois at Chicago Director of Consultation Liaison Service, Advocate Christ Medical Center Director of the Older Adult Program,
More informationDEMENTIA, THE BRAIN AND HOW IT WORKS AND WHY YOU MATTER
OVERCOMING THE CHALLENGES OF MANAGING CHRONIC DISEASES IN PERSONS WITH DEMENTIA DEMENTIA, THE BRAIN AND HOW IT WORKS AND WHY YOU MATTER LEARNING OBJECTIVES Be familiar with the diagnostic criteria for
More informationThe ABCs of Dementia Diagnosis
The ABCs of Dementia Diagnosis Dr. Robin Heinrichs, Ph.D., ABPP Board Certified Clinical Neuropsychologist Associate Professor, Psychiatry & Behavioral Sciences Director of Neuropsychology Training What
More informationDSM-5 MAJOR AND MILD NEUROCOGNITIVE DISORDERS (PAGE 602)
SUPPLEMENT 2 RELEVANT EXTRACTS FROM DSM-5 The following summarizes the neurocognitive disorders in DSM-5. For the complete DSM-5 see Diagnostic and Statistical Manualof Mental Disorders, 5th edn. 2013,
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationA Fresh View of Cognitive Disorders in Older Adults: New Classification and Screening Strategies
A Fresh View of Cognitive Disorders in Older Adults: New Classification and Screening Strategies Lynda Mackin, PhD, AGPCNP-BC, CNS University of California San Francisco School of Nursing 1 Alzheimer s
More informationEvaluation and Treatment of Dementia
Evaluation and Treatment of Dementia Jeffrey M. Burns, MD Edward H. Hashinger Professor of Neurology Co-Director, KU Alzheimer s Disease Center Director, Clinical and Translational Science Unit Disclosures
More informationAlzheimer s Disease without Dementia
Alzheimer s Disease without Dementia Dr Emer MacSweeney CEO & Consultant Neuroradiologist Re:Cognition Health London Osteopathic Society 13 September 2016 Early diagnosis of Alzheimer s Disease How and
More informationPocket Reference to Alzheimer s Disease Management
Pocket Reference to Alzheimer s Disease Management Pocket Reference to Alzheimer s Disease Management Anna Burke, MD Geriatric Psychiatrist, Dementia Specialist Geri R Hall, PhD, ARNP, GCNS, FAAN Advanced
More informationDementia. Aetiology, pathophysiology and the role of neuropsychological testing. Dr Sheng Ling Low Geriatrician
Dementia Aetiology, pathophysiology and the role of neuropsychological testing Dr Sheng Ling Low Geriatrician Topics to cover Why is dementia important What is dementia Differentiate between dementia,
More informationFRONTOTEMPORAL DEGENERATION: OVERVIEW, TRENDS AND DEVELOPMENTS
FRONTOTEMPORAL DEGENERATION: OVERVIEW, TRENDS AND DEVELOPMENTS Norman L. Foster, M.D. Director, Center for Alzheimer s Care, Imaging and Research Chief, Division of Cognitive Neurology, Department of Neurology
More informationFact Sheet Alzheimer s disease
What is Alzheimer s disease Fact Sheet Alzheimer s disease Alzheimer s disease, AD, is a progressive brain disorder that gradually destroys a person s memory and ability to learn, reason, make judgements,
More informationDementia. Stephen S. Flitman, MD Medical Director 21st Century Neurology
Dementia Stephen S. Flitman, MD Medical Director 21st Century Neurology www.neurozone.org Dementia is a syndrome Progressive memory loss, plus Progressive loss of one or more cognitive functions: Language
More informationCognitive Screening in Risk Assessment. Geoffrey Tremont, Ph.D. Rhode Island Hospital & Alpert Medical School of Brown University.
Cognitive Screening in Risk Assessment Geoffrey Tremont, Ph.D. Rhode Island Hospital & Alpert Medical School of Brown University Outline of Talk Definition of Dementia and MCI Incidence and Prevalence
More informationStephen Salloway, M.D., M.S. Disclosure of Interest
Challenges in the Early Diagnosis of Alzheimer s Disease Stephen Salloway, MD, MS Professor of Neurology and Psychiatry Alpert Medical School, Brown University 2 nd Annual Early Alzheimer s Educational
More informationThe Person: Dementia Basics
The Person: Dementia Basics Objectives 1. Discuss how expected age related changes in the brain might affect an individual's cognition and functioning 2. Discuss how changes in the brain due to Alzheimer
More information8/14/2018. The Evolving Concept of Alzheimer s Disease. Epochs of AD Research. Diagnostic schemes have evolved with the research
The Evolving Concept of Alzheimer s Disease David S. Geldmacher, MD, FACP Warren Family Endowed Chair in Neurology Department of Neurology UAB School of Medicine Epochs of AD Research Epoch Years Key Event
More informationAnxiety, Depression, and Dementia/Alzheimer Disease: What are the Links?
The 2016 Annual Public Educational Forum Anxiety, Depression, and Dementia/Alzheimer Disease: What are the Links? Mary Ganguli MD MPH Professor of Psychiatry, Neurology, and Epidemiology, University of
More informationThe Basics of Alzheimer s Disease
2017 Memory Loss Conference The Basics of Alzheimer s Disease Tom Ala, MD Center for Alzheimer s Disease and Related Disorders Southern Illinois University School of Medicine Springfield, Illinois SIU
More informationHow can the new diagnostic criteria improve patient selection for DM therapy trials
How can the new diagnostic criteria improve patient selection for DM therapy trials Amsterdam, August 2015 Bruno Dubois Head of the Dementia Research Center (IMMA) Director of INSERM Research Unit (ICM)
More information#CHAIR2015. Miami, Florida. September 24 26, JW Marriott Miami. Sponsored by
#CHAIR2015 September 24 26, 2015 JW Marriott Miami Miami, Florida Sponsored by Case Challenge Workshop Alzheimer s Disease Anand Kumar, MD University of Illinois at Chicago, College of Medicine Chicago,
More informationAlzheimer s Disease Update: From Treatment to Prevention
Alzheimer s Disease Update: From Treatment to Prevention Jeffrey M. Burns, MD Edward H. Hashinger Professor of Medicine Co-Director, KU Alzheimer s Disease Center Director, Clinical and Translational Science
More informationThe added value of the IWG-2 diagnostic criteria for Alzheimer s disease
The added value of the IWG-2 diagnostic criteria for Alzheimer s disease Miami, January 2016 Bruno Dubois Head of the Dementia Research Center (IMMA) Director of INSERM Research Unit (ICM) Salpêtrière
More informationGERIATRIC MENTAL HEALTH AND MEDICATION TREATMENT
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences GERIATRIC MENTAL HEALTH AND MEDICATION TREATMENT RUTH KOHEN ASSOCIATE PROFESSOR UW DEPARTMENT OF PSYCHIATRY 5-4-2017
More informationDementia Prepared by: Joanne Leung Psychiatry Resident, University of Toronto
Dementia Prepared by: Joanne Leung Psychiatry Resident, University of Toronto Dementias are acquired neurodegenerative disorders involving a syndrome of cognitive impairment accompanied with social and
More informationAlzheimer's Disease. Dementia
Alzheimer's Disease Victor W. Henderson, MD, MS Departments of Health Research & Policy (Epidemiology) and of Neurology & Neurological Sciences Stanford University Director, Stanford Alzheimer s Disease
More informationALZHEIMER S DISEASE. Mary-Letitia Timiras M.D. Overlook Hospital Summit, New Jersey
ALZHEIMER S DISEASE Mary-Letitia Timiras M.D. Overlook Hospital Summit, New Jersey Topics Covered Demography Clinical manifestations Pathophysiology Diagnosis Treatment Future trends Prevalence and Impact
More informationPart 2: Early detection, assessment and treatment in relation to the new guidelines. Christopher Patterson McMaster University
Part 2: Early detection, assessment and treatment in relation to the new guidelines Christopher Patterson McMaster University C. Patterson MD, FRCPC Division of Geriatric Medicine, McMaster University
More informationRecommendations for the Diagnosis and Treatment of Dementia 2012
Recommendations for the Diagnosis and Treatment of Dementia 2012 Based on the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (4 th CCCDTD) 2012 Gauthier S, Patterson C, Chertkow
More informationUnderstanding Symptoms, Causes, and Risks for Alzheimer s Disease
Understanding Symptoms, Causes, and Risks for Alzheimer s Disease Gene E. Alexander, Ph.D., Professor of Psychology, Neuroscience, and Physiological Sciences; Director, Brain Imaging, Behavior & Aging
More informationMoving Targets: An Update on Diagnosing Dementia in the Clinic
Moving Targets: An Update on Diagnosing Dementia in the Clinic Eric McDade DO Department of Neurology School of Medicine Alzheimer Disease Research Center Disclosures No relevant financial disclosures
More informationCognitive Evaluation in Primary Care. Scott T. Larson, MD Clinical Assistant Professor University of Iowa
Cognitive Evaluation in Primary Care Scott T. Larson, MD Clinical Assistant Professor University of Iowa scott-larson@uiowa.edu Objectives Understand the subtypes of dementia, and the DSM-5 categorization
More informationBrain Health and Risk Factors for Dementia
Welcome To Brain Health and Risk Factors for Dementia Presented by Kamal Masaki, MD Professor and Chair Department of Geriatric Medicine John A. Burns School of Medicine, UH Manoa April 4, 2018 10:00 11:00
More informationDEMENTIA 101: WHAT IS HAPPENING IN THE BRAIN? Philip L. Rambo, PhD
DEMENTIA 101: WHAT IS HAPPENING IN THE BRAIN? Philip L. Rambo, PhD OBJECTIVES Terminology/Dementia Basics Most Common Types Defining features Neuro-anatomical/pathological underpinnings Neuro-cognitive
More informationASHA Comments* (ASHA Recommendations Compared to DSM-5 Criteria) Austism Spectrum Disorder (ASD)
DSM-5 (Criteria and Major Changes for SLP-Related Conditions) Individuals meeting the criteria will be given a diagnosis of autism spectrum disorder with three levels of severity based on degree of support
More informationThe current state of healthcare for Normal Aging, Mild Cognitive Impairment, & Alzheimer s Disease
The current state of healthcare for Normal Aging, g, Mild Cognitive Impairment, & Alzheimer s Disease William Rodman Shankle, MS MD FACP Director, Alzheimer s Program, Hoag Neurosciences Institute Neurologist,
More informationI have no relevant financial disclosures
1 ADVANCED INSIGHTS INTO THE PREVENTION, TREATMENT AND MANAGEMENT OF ALZHEIMER S DISEASE Naushira Pandya, MD, CMD, FACP Professor and Chair, Department of Geriatrics Director, Geriatrics Education Center
More informationAssessing and Managing the Patient with Cognitive Decline
Assessing and Managing the Patient with Cognitive Decline Center of Excellence For Alzheimer s Disease for State of NY Capital Region Alzheimer s Center of Albany Medical Center Earl A. Zimmerman, MD Professor
More informationClinical Diagnosis. Step 1: Dementia or not? Diagnostic criteria for dementia (DSM-IV)
Step 1: Dementia or not? Diagnostic criteria for dementia (DSM-IV) A. The development of multiple cognitive deficits manifested by both 1 and 2 1 1. Memory impairment 2. One (or more) of the following
More informationDementia and Alzheimer s disease
Since 1960 Medicine Korat โรงพยาบาลมหาราชนครราชส มา Dementia and Alzheimer s disease Concise Reviews PAWUT MEKAWICHAI MD DEPARTMENT of MEDICINE MAHARAT NAKHON RATCHASIMA HOSPITAL 1 Prevalence Increase
More informationCHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE
CHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE 5.1 GENERAL BACKGROUND Neuropsychological assessment plays a crucial role in the assessment of cognitive decline in older age. In India, there
More informationSHARED CARE OF MCI/EARLY DEMENTIA
SHARED CARE OF MCI/EARLY DEMENTIA BY DR. OLUFEMI BANJO MD, DTM, DCP, DIPA&DS, DHM, M.Med.Sc, FRCP(C) GERIATRIC PSYCHIATRIST. ASSISTANT MEDICAL DIRECTOR, ADULT MENTAL HEALTH AND ADDICTION, GRAND RIVER HOSPITAL
More informationCarol Manning, PhD, ABPP-CN Director, Memory Disorders Clinic University of Virginia
Carol Manning, PhD, ABPP-CN Director, Memory Disorders Clinic University of Virginia Case Study Mr. S. is a 74 year old man who has smoked for 20 years. He is overweight, has high cholesterol and high
More informationDavid A Scott Lis Evered. Department of Anaesthesia and Acute Pain Medicine St Vincent s Hospital, Melbourne University of Melbourne
David A Scott Lis Evered Department of Anaesthesia and Acute Pain Medicine St Vincent s Hospital, Melbourne University of Melbourne This talk will include live polling so please be sure to have the meeting
More informationProf Tim Anderson. Neurologist University of Otago Christchurch
Prof Tim Anderson Neurologist University of Otago Christchurch Tim Anderson Christchurch Insidious cognitive loss From subjective memory complaints (SMC) to dementia Case 1. AR. 64 yrs Male GP referral
More informationUSE OF BIOMARKERS TO DISTINGUISH SUBTYPES OF DEMENTIA. SGEC Webinar Handouts 1/18/2013
Please visit our website for more information http://sgec.stanford.edu/ SGEC Webinar Handouts 1/18/2013 2013 WEBINAR SERIES STATE OF THE SCIENCE: DEMENTIA EVALUATION AND MANAGEMENT AMONG DIVERSE OLDER
More informationAlzheimer s Disease. Pathophysiology: Alzheimer s disease (AD) is a progressive dementia affecting cognition, behavior,
2 Alzheimer s Disease Alzheimer s disease (AD) is a progressive dementia affecting cognition, behavior, and functional status with no known cause or cure. Patients eventually lose cognitive, analytical,
More informationRecognizing Dementia can be Tricky
Dementia Abstract Recognizing Dementia can be Tricky Dementia is characterized by multiple cognitive impairments that cause significant functional decline. Based on this brief definition, the initial expectation
More informationNovember 16-18, 2017 Hotel Monteleone New Orleans, LA. Provided by
November 16-18, 2017 Hotel Monteleone New Orleans, LA Provided by Major Neurocognitive Disorder: The Beginning and the End. Making the Diagnosis and Addressing Distressing Behavior W. Vaughn McCall, MD,
More informationCaring Sheet #11: Alzheimer s Disease:
CARING SHEETS: Caring Sheet #11: Alzheimer s Disease: A Summary of Information and Intervention Suggestions with an Emphasis on Cognition By Shelly E. Weaverdyck, PhD Introduction This caring sheet focuses
More informationEarly Diagnosis of Alzheimer s Disease and MCI via Imaging and Pattern Analysis Methods. Christos Davatzikos, Ph.D.
Early Diagnosis of Alzheimer s Disease and MCI via Imaging and Pattern Analysis Methods Christos Davatzikos, Ph.D. Director, Section of Biomedical Image Analysis Professor of Radiology http://www.rad.upenn.edu/sbia
More informationThe Aging Brain The Aging Brain
The Aging Brain The Aging Brain R. Scott Turner, MD, PhD Director, Memory Disorders Program Professor, Department of Neurology Georgetown University Washington, DC memory.georgetown.edu rst36@georgetown.edu
More informationP20.2. Characteristics of different types of dementia and challenges for the clinician
P20.2. Characteristics of different types of dementia and challenges for the clinician, professor Danish Dementia Research Center Rigshospitalet, University of Copenhagen (Denmark) This project has received
More informationCommunity Information Forum September 20, 2014
Community Information Forum September 20, 2014 Dr. David B. Hogan Brenda Strafford Foundation Chair in Geriatrics Medicine University of Calgary Important to note: The slides used during Dr. Hogan's presentation
More informationIssues to Consider in the Clinical Evaluation and Development of Drugs for Alzheimer s Disease. The University of Tokyo Hospital
Project to Promote the Development of Innovative Pharmaceuticals, Medical Devices, and Regenerative Medical Products (Ministry of Health, Labour, and Welfare) Regulatory Science Research for the Establishment
More informationNeuro degenerative PET image from FDG, amyloid to Tau
Neuro degenerative PET image from FDG, amyloid to Tau Kun Ju Lin ( ) MD, Ph.D Department of Nuclear Medicine and Molecular Imaging Center, Chang Gung Memorial Hospital ( ) Department of Medical Imaging
More informationAlzheimer's Disease An update on diagnostic criteria & Neuropsychiatric symptoms. l The diagnosis of AD l Neuropsychiatric symptoms l Place of the ICT
Alzheimer's Disease An update on diagnostic criteria & Neuropsychiatric symptoms State of the art lecture March 4-2012 Philippe H Robert, Philippe Nice - France Robert The diagnosis of AD Neuropsychiatric
More information8/24/18. Dementia. Risk of Dementia Following Traumatic Brain Injury: A Review of the Literature. Media Presence. Media Presence
Risk of Dementia Following Traumatic Brain Injury: A Review of the Literature Media Presence Carlos Marquez de la Plata, Ph.D. & Jeff Schaffert, M.S. Media Presence Dementia What is dementia? Dementia
More informationDementia, Cognitive Aging Services and Support
Dementia, Cognitive Aging Services and Support Ronald C. Petersen, Ph.D., M.D. Professor of Neurology Mayo Clinic College of Medicine Rochester, MN NASUAD Washington September 2, 2015 Disclosures Pfizer,
More informationWhat is dementia? What is dementia?
What is dementia? What is dementia? What is dementia? Dementia is an umbrella term for a range of progressive conditions that affect the brain. It has been identified that there are over 200 subtypes of
More informationCognitive Assessment 4/29/2015. Learning Objectives To be able to:
Supporting the Desire to Age in Place: Important Considerations for the Aging Population AGENDA 8:45 9:00 AM Geriatric Principles Robert L. Kane, MD *9:00 9:55 AM Cognitive Assessments Ed Ratner, MD 10:00
More informationWhat is Neuropsychology?
Alzheimer s Disease Neurological Bases and Informed Behavioral Interventions Peter T. Keenan Clinical Neuropsychologist Marshfield Clinic Minocqua Center What is Neuropsychology? Science of the relationship
More informationSeptember 26 28, 2013 Westin Tampa Harbour Island. Co-sponsored by
September 26 28, 2013 Westin Tampa Harbour Island Co-sponsored by From Brains at Risk to Cognitive Dysfunction: The Role of Vascular Pathology Ralph Sacco, MD, MS, FAHA, FAAN Miller School of Medicine
More informationPatterns of Cognitive Impairment in Dementia
Patterns of Cognitive Impairment in Dementia Lindsay R. Clark, PhD Assistant professor (CHS) Department of Medicine - Division of Geriatrics & Gerontology UW-Madison School of Medicine & Public Health
More informationUDS version 3 Summary of major changes to UDS form packets
UDS version 3 Summary of major changes to UDS form packets from version 2 to VERSION 3 february 18 final Form A1: Subject demographics Updated question on principal referral source to add additional options
More informationDo not copy or distribute without permission. S. Weintraub, CNADC, NUFSM, 2009
Sandra Weintraub, Ph.D. Clinical Core Director, Cognitive Neurology and Alzheimer s Disease Center Northwestern University Feinberg School of Medicine Chicago, Illinois Dementia: a condition caused by
More informationPersonal Reflections on the Design and Delivery of Services to Those with Cognitive Disorders
Personal Reflections on the Design and Delivery of Services to Those with Cognitive Disorders Dr. David B. Hogan Brenda Strafford Foundation Chair in Geriatric Medicine University of Calgary None to declare
More informationImproving diagnosis of Alzheimer s disease and lewy body dementia. Brain TLC October 2018
Improving diagnosis of Alzheimer s disease and lewy body dementia Brain TLC October 2018 Plan for this discussion: Introduction to AD and LBD Why do we need to improve diagnosis? What progress has been
More informationMemory Matters: Learning Objectives: Synapses, Age, and Health. Neuronal Synapses DISCLOSURE DECLARATION. Cognition and Normal Aging
Standard Deviations from Mean Memory Matters: Preventing and Treating Late-Life, Cognitive Decline Daniel L. Murman, MD, MS Director, Behavioral and Geriatric Neurology Program Professor & Vice Chair,
More informationIntroduction, use of imaging and current guidelines. John O Brien Professor of Old Age Psychiatry University of Cambridge
Introduction, use of imaging and current guidelines John O Brien Professor of Old Age Psychiatry University of Cambridge Why do we undertake brain imaging in AD and other dementias? Exclude other causes
More informationDementia and Healthy Ageing : is the pathology any different?
Dementia and Healthy Ageing : is the pathology any different? Professor David Mann, Professor of Neuropathology, University of Manchester, Hope Hospital, Salford DEMENTIA Loss of connectivity within association
More informationLatest Methods to Early Detection for Alzheimer's: Cognitive Assessments and Diagnostic Tools in Practice
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/alzheimers-disease-towards-earlier-detection/latest-methods-earlydetection-alzheimers-cognitive-assessments-and-diagnostic-tools-practice/8321/
More informationDelirium & Dementia. Nicholas J. Silvestri, MD
Delirium & Dementia Nicholas J. Silvestri, MD Outline Delirium vs. Dementia Neural pathways relating to consciousness Encephalopathy Stupor Coma Dementia Delirium vs. Dementia Delirium Abrupt onset Lasts
More informationJanuary 18 th, 2018 Brixen, Italy
From Subjective Cognitive Decline to Alzheimer s Disease: the predictive role of neuropsychological, personality and cognitive reserve features. A 7-years Follow-Up study. S. Mazzeo *, V. Bessi *, S. Padiglioni
More informationUNIVERSITY OF WESTERN ONTARIO
UNIVERSITY OF WESTERN ONTARIO Vladimir Hachinski, CM, MD, FRCPC, DSc Department of Clinical Neurological Sciences University of Western Ontario London, Ontario, Canada Vladimir.hachinski@lhsc.on.ca ALZHEIMER
More information3/6/2019 DIAGNOSIS OF DEMENTIA IN THE OUTPATIENT SETTING FINANCIAL DISCLOSURES LEARNING OBJECTIVES
DIAGNOSIS OF DEMENTIA IN THE OUTPATIENT SETTING MILTA LITTLE, DO, CMD DUKE UNIVERSITY SCHOOL OF MEDICINE FINANCIAL DISCLOSURES Dr. Little has no relevant financial disclosures to report Dr. Little will
More informationDiagnosis and management of non-alzheimer dementias. Melissa Yu, M.D. Department of Neurology
Diagnosis and management of non-alzheimer dementias Melissa Yu, M.D. Department of Neurology AGENDA Introduction When to think of alternate diagnoses Other forms of dementia Other reasons for confusion
More informationMentis Cura November
Mentis Cura November 29 2012 www.mentiscura.com New Facts on Alzheimer s Death rank nr. 2-5 in western countries Fastest growing disease in: Cost Incedence Death rate People with Alzheimer s 2012 36 million
More informationResearch ALZHEIMER S DISEASE AND RISK FACTORS
Research ALZHEIMER S DISEASE AND RISK FACTORS What is Alzheimer s disease? Alzheimer s disease is the most common of a large group of disorders known as dementias. It is an irreversible disease of the
More informationChanging diagnostic criteria for AD - Impact on Clinical trials
Changing diagnostic criteria for AD - Impact on Clinical trials London, November 2014 Bruno Dubois Head of the Dementia Research Center (IMMA) Director of INSERM Research Unit (ICM) Salpêtrière Hospital
More informationGetting Help for Patients with Dementia and their Caregivers. Erica Salamida Associate Director of Programs and Services Alzheimer s Association-NENY
Getting Help for Patients with Dementia and their Caregivers Erica Salamida Associate Director of Programs and Services Alzheimer s Association-NENY In this session you will learn about: Symptoms of dementia,
More informationCan aspirin slow cognitive decline and the onset of dementia? The ASPREE study. Mark Nelson on behalf of ASPREE Investigators
Can aspirin slow cognitive decline and the onset of dementia? The ASPREE study. Mark Nelson on behalf of ASPREE Investigators ASPREE Randomized, double-blind, placebo-controlled trial for extending healthy
More information